Cell News and Research

RSS

First patient treated in multicentre Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine for melanoma

Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, today announces the enrolment and treatment of the first patient in its multicentre Phase I clinical trial of SCIB1, its DNA ImmunoBody® vaccine being developed for the treatment of melanoma. The trial will evaluate the safety and tolerability of SCIB1 in patients with late stage melanoma.

15 Jun 2010

New insight into sleeping sickness parasite

Fresh discoveries about the parasite that causes sleeping sickness could lead to new avenues of research into treatments for the disease.

15 Jun 2010

Tel Aviv University research suggests link between IVF treatments and autism

The first "test tube baby" was born in 1978. With advances in reproductive science, an estimated one percent of all American babies are now born each year through in vitro fertilization. But IVF and other assisted fertility treatments may be solving one problem by creating another, suggests new evidence from Tel Aviv University.

15 Jun 2010

Regulatory T cells delay arrival of TB-fighting T cells

The outcome of tuberculosis infection in mice depends in part on how quickly bacteria-fighting T cells can get to the lungs. According to a new study that will appear online on June 14th in the Journal of Experimental Medicine, another group of T cells delays their arrival.

15 Jun 2010

Depression and other stress-related psychiatric disorders in women may have biological basis: Research

There may be a biological reason why depression and other stress-related psychiatric disorders are more common among women compared to men. Studying stress signaling systems in animal brains, neuroscience researchers found that females are more sensitive to low levels of an important stress hormone and less able to adapt to high levels than males.

15 Jun 2010

Sulindac shuts down cancer cell growth, initiates cell death: Study

Without knowing exactly why, scientists have long observed that people who regularly take non-steroidal anti-inflammatory drugs like aspirin have lower incidences of certain types of cancer. Now, in a study appearing in Cancer Cell on June 15, investigators at Sanford-Burnham Medical Research Institute and their colleagues have figured out how one NSAID, called Sulindac, inhibits tumor growth.

15 Jun 2010

Researchers discover microRNA biomarkers to treat patients with SCLC

Researchers at the Translational Genomics Research Institute, the Van Andel Research Institute and the Virginia G. Piper Cancer Center at Scottsdale Healthcare have discovered a biomarker that could help in the treatment of patients with an aggressive type of lung cancer.

15 Jun 2010

Micromet's blinatumomab demonstrates potential to change outcome for patients with ALL

Micromet, Inc. today announced the presentation of updated results from a Phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL). Results of the analysis demonstrate that a prolonged hematologic relapse free survival was observed in patients treated with blinatumomab.

15 Jun 2010

Pediatric oncologist describes current state of science in combating neuroblastoma

Pediatric oncologist John M. Maris, M.D., describes the current state of the science in combating neuroblastoma, the most common solid cancer of early childhood. In his article in the June 10, 2010 New England Journal of Medicine, "Recent Advances in Neuroblastoma," Maris reviews the field's latest research knowledge—much of it based on efforts by Maris and his colleagues at The Children's Hospital of Philadelphia.

15 Jun 2010

Trubion announces Pfizer's decision to discontinue development of TRU-015 for RA

Trubion Pharmaceuticals, Inc. today announced Pfizer's decision to discontinue development of TRU-015 (PF-05212374), an investigational drug in Phase 2 evaluation for the treatment of rheumatoid arthritis (RA) developed under the companies' CD20 collaboration. However, Pfizer has confirmed that it will continue to develop SBI-087 (PF-05230895), Trubion's next-generation, humanized, subcutaneous CD20 RA product candidate also in Phase 2 clinical evaluation.

15 Jun 2010

New research shows astrocytes play important role in the function of nerve cells

Astrocytes are the most common type of cell in the brain and play an important role in the function of neurons - nerve cells. New research from the University of Gothenburg, Sweden, shows that they are also directly involved in the regulation of signalling between neurons.

15 Jun 2010

Entomologists to develop genetically engineered bacteria for killing mosquito larvae

Roughly half the world's population still lives in areas at risk of malaria transmission. Even in the United States, 1500 cases of malaria are reported annually on average.

15 Jun 2010

CLC-5 protein plays active part in inherited kidney disorder: Scientists

Scientists from the University of Leeds have discovered the mechanisms of a protein known to play an active part in the inherited kidney disorder, Dent's disease. The findings provide a new focus for future therapies for the disease, for which there is currently no cure.

15 Jun 2010

FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS

Genzyme Corporation announced today that its alemtuzumab for multiple sclerosis development program has been granted Fast Track status by the U.S. Food and Drug Administration (FDA). This designation covers patients with relapsing-remitting forms of the disease.

15 Jun 2010

Insulin-producing beta cells can proliferate in patients recently diagnosed with type 1 diabetes: Researchers

Researchers from the Peninsula Medical School, working in collaboration with colleagues from Glasgow Royal Infirmary and the University of Brighton, have used a unique collection of pancreas specimens taken from patients who died soon after diagnosis of type 1 diabetes to show that they respond to the ongoing process of destruction by inducing their islet cells to proliferate.

15 Jun 2010

New Brunswick Scientific, Pall partner to develop new disposable bioreactor systems

New Brunswick Scientific, an Eppendorf Company, and Pall Corporation today announced a joint product development and marketing agreement to create and supply new disposable bioreactor systems.

From Pall Corporation 14 Jun 2010

Cytori Therapeutics enters $20 million secured loan facility

Cytori Therapeutics entered into a $20 million secured loan facility from GE Capital, Healthcare Financial Services, Oxford Finance Corporation, and Silicon Valley Bank. The loan funded June 14, 2010.

14 Jun 2010

Asterand subsidiary BioSeek signs agreement with Amylin

Asterand plc, a leading provider of human tissue and human tissue-based research services to pharmaceutical and biotechnology companies engaged in drug discovery, today announces that its subsidiary BioSeek, LLC, a pioneer in the application of predictive human biology to drug discovery, has signed a one-year collaboration agreement with Amylin Pharmaceuticals, Inc.

14 Jun 2010

New path involving "innocent spectators" to defeat systemic sclerosis

There is a new path to defeat systemic sclerosis, also called scleroderma because of the hardening of the skin of the patients (from Greek skleros, "hard", and derma, "skin"). This path involves the B-cell of the immune system, so far only considered "innocent spectators," as Catholic University rheumatologist Gianfranco Ferraccioli, among the authors of the important research, puts it.

14 Jun 2010

Esperion, Cleveland Clinic collaborate to research new HDL therapies for cardiovascular disease

Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the establishment of a collaborative research agreement with Cleveland Clinic, one of the world's leading academic medical centers. The collaboration will work to advance research targeting new HDL therapies to treat cardiovascular disease.

14 Jun 2010

Cell News and Research

First patient treated in multicentre Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine for melanoma

New insight into sleeping sickness parasite

Tel Aviv University research suggests link between IVF treatments and autism

Regulatory T cells delay arrival of TB-fighting T cells

Depression and other stress-related psychiatric disorders in women may have biological basis: Research

Sulindac shuts down cancer cell growth, initiates cell death: Study

Researchers discover microRNA biomarkers to treat patients with SCLC

Micromet's blinatumomab demonstrates potential to change outcome for patients with ALL

Pediatric oncologist describes current state of science in combating neuroblastoma

Trubion announces Pfizer's decision to discontinue development of TRU-015 for RA

New research shows astrocytes play important role in the function of nerve cells

Entomologists to develop genetically engineered bacteria for killing mosquito larvae

CLC-5 protein plays active part in inherited kidney disorder: Scientists

FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS

Insulin-producing beta cells can proliferate in patients recently diagnosed with type 1 diabetes: Researchers

New Brunswick Scientific, Pall partner to develop new disposable bioreactor systems

Cytori Therapeutics enters $20 million secured loan facility

Asterand subsidiary BioSeek signs agreement with Amylin

New path involving "innocent spectators" to defeat systemic sclerosis

Esperion, Cleveland Clinic collaborate to research new HDL therapies for cardiovascular disease

Industry focus eBook - Cell and gene therapy (2nd edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics